Equity
Hungary's Richter inks exclusive license deal for Australia, New Zealand
Richter to supply cariprazine
Richter announced before the opening bell on the Budapest Stock Exchange (BSE) on Friday the signing of an exclusive license agreement with Seqirus to commercialize cariprazine in Australia and New Zealand.Under the terms of the agreement, Richter will be responsible for product supply and Seqirus will be responsible for the registration and commercialisation of the product in Australia and New Zealand. Richter will receive an upfront payment as well as milestone payments from Seqirus.
“We are pleased with the partnership established, which provides an option to making available worldwide cariprazine for those who are suffering from mental illnesses", said Gábor Orbán, Chief Executive Officer of Richter.
“We are very excited to be working with Richter on the commercialisation of this innovative treatment for schizophrenia. This product is an important addition to Seqirus’ growing product range and strengthens our broad portfolio of in-licensed medicines in Australia and New Zealand," said Dr Lorna Meldrum, Vice President of Commercial Operations, Seqirus Asia Pacific.
About Seqirus
In Australia and New Zealand, Seqirus is a fully integrated pharmaceutical company operating with expertise in specialty and primary care pharmaceuticals and vaccines. The Seqirus sales and marketing teams are multi-award winning and recognised as leaders within the pharmaceutical industry.Seqirus is part of CSL Limited, headquartered in Melbourne, Australia. The CSL Group of companies employs more than 22,000 people with operations in more than 60 countries.
Seqirus was established on 31 July 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. It has leading R&D capabilities, a broad portfolio of differentiated products and a commercial presence in more than 20 countries.
